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BoneIt has long been known that many bone diseases, including osteoporosis, involve abnormalities in osteoclastic
bone resorption. As a result, there has been intense study of the mechanisms that regulate both the
differentiation and bone resorbing function of osteoclast cells. Calcium (Ca2+) signaling appears to play a
critical role in the differentiation and functions of osteoclasts. Cytoplasmic Ca2+ oscillations occur during
RANKL-mediated osteoclastogenesis. Ca2+ oscillations provide a digital Ca2+ signal that induces osteoclasts to
up-regulate and autoamplify nuclear factor of activated T cells c1 (NFATc1), a Ca2+/calcineurin-dependent
master regulator of osteoclastogenesis. Here we review previous studies on Ca2+ signaling in osteoclasts as
well as recent breakthroughs in understanding the basis of RANKL-induced Ca2+ oscillations, and we discuss
possible molecular players in this specialized Ca2+ response that appears pivotal for normal bone function.
This article is part of a Special Issue entitled: 11th European Symposium on Calcium.opean Symposium on Calcium.
+1 919 541 4898.
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Bones are dynamic living organs that are constantly renewed
throughout one's life. This constant and balanced bone turnover relies
on the process of bone remodeling mediated by osteoblasts that form
bone and osteoclasts that resorb bone [57]. Imbalance between
osteoblastic bone production and osteoclastic bone resorption favoring
bone resorption is known to occur in many bone diseases such as
postmenopausal osteoporosis, arthritis, and bone tumors [36,43].
Accordingly, most drugs used in the treatment of osteoporosis are
anti-resorptive in nature. Bisphosphonates, estrogen, and calcitonin are
currently the main pharmacological approaches for prevention of bone
loss [28,35]. However, there are many side effects from the long-term
use of these drugs such as constipation, diarrhea, tumorigenic and
cardiovascular effects, and osteonecrosis of the jaw [28,35]. As a result,
there have been considerable efforts to develop new therapeutic targets
for the treatment or prevention of bone loss.
The activation of the receptor activator of nuclear factor-κB (RANK)
by its speciﬁc ligand (RANKL) is an essential initiating signal for
osteoclastogenesis. One of the key downstream signals in the RANK/
RANKL pathway is the Ca2+ dependent calcineurin/NFAT pathway,
implicating a signiﬁcant role for Ca2+ signaling. We will discuss the
RANKL-dependent pathway and the role of Ca2+ signaling in more
detail below.2. Ca2+ mobilization in osteoclasts
Ca2+ serves as a ubiquitous second messenger that can speciﬁcally
mediate and regulate a variety of downstream signaling pathways [1].
Many different stimuli have been shown to regulate Ca2+ concentra-
tions in osteoclasts. Extracellular acidiﬁcation caused a decrease in
intracellular Ca2+ concentration in isolated chickenosteoclastswhich in
turn enhanced attachment of cells to bone matrix [45]. Yu and Ferrier
[56] reported that ATP triggers a transient rise in intracellular Ca2+
concentrations in rabbit osteoclasts. They concluded that P2 purinergic
receptors are involved in this rise of Ca2+. The same group demon-
strated that the ATP-induced Ca2+ rise was smaller and more transient
in Ca2+ free buffer, suggesting that activation of Ca2+ inﬂux contributes
to the Ca2+ signal in osteoclasts. αvβ3 integrin receptors are highly
expressed in osteoclasts and known tobe important for the function and
adhesionofosteoclasts on thebonematrix [8,10,15,16]. Activationof the
integrin receptor by speciﬁc peptides caused a transient Ca2+ response
in the absence of extracellular Ca2+ [38]. Xia and Ferrier [50] reported
thatmechanical perturbationof osteoclasts induced aCa2+mobilization
response whose amplitude and duration were dependent on the
extracellular Ca2+ concentration. Radding et al. [34] observed intracel-
lular Ca2+puffs in acid-secreting osteoclasts,which they suggestmaybe
involved in signaling acid secretion for bone resorption.
Themost commonmechanism of Ca2+mobilization by extracellular
stimuli involves activation of phospholipase C (PLC)-coupled receptors,
leading to the production of inositol-1,4,5- trisphosphate (IP3). IP3 binds
to and activates the IP3 receptor (IP3R) resulting inCa2+ release fromthe
endoplasmic reticulum (ER) [1]. IP3 has been shown to induce Ca2+
release from bone cells including osteoblasts and osteoclasts [11].
Yaroslavskiy et al. [52] demonstrated that the IP3R type 1 is required for
activation of Ca2+-dependent μ-calpain and nitric oxide-induced Ca2+
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immunoﬂuorescence, reported the presence in rat osteoclasts of all
three isotypes of IP3R. Interestingly,Morikawa et al. found that IP3R type
3 is localized to podosomes where osteoclasts adhere to bone,
suggesting a potential role of IP3R in the formation or function of
podosomes. Malgaroli et al. [24] reported that osteoclast cells sense high
extracellular Ca2+ and respond with increased intracellular Ca2+
transients that may be linked to activation of PLC. Similarly, Zaidi et al.
[58] reported that high extracellular Ca2+ induces elevation of intracel-
lular Ca2+ in isolated rat osteoclasts. They also suggest that extracellular
Ca2+ regulates bone resorption activity of osteoclasts. Subsequently it
was conﬁrmed by Seuwen et al. [37] that high extracellular Ca2+ elicits
Ca2+ release associated with production of inositol phosphate in
osteoclast-like cells, suggesting the involvement of Ca2+ sensing
receptors in Ca2+ signaling in osteoclasts. By use of a Ca2+ sensing
receptor knockout mouse as well as a Ca2+ receptor dominant negative
construct, Mentaverri et al. [27] provided evidence that Ca2+ sensing
receptors play a critical role in osteoclast differentiation and apoptosis.
Involvement of the ryanodine receptor (RyR), an intracellular Ca2+
release channel, in the activation of Ca2+ mobilization in osteoclasts
was investigated by several groups. Zaidi et al. [60] reported that Ni2+
induced cytosolic Ca2+ release in rat osteoclasts and this responsewas
blocked by ryanodine, suggesting the presence of Ca2+ releasing
ryanodine receptors. Similarly, Shankar [40] showed that low
concentrations of caffeine, a RyR agonist, induce cytosolic Ca2+
mobilization in isolated rat osteoclasts. One group has suggested that
RyRs are expressed in the plasma membrane of osteoclasts,
functioning as extracellular Ca2+ sensing receptor [30,61]. However,
this idea has not as yet gained general acceptance [6].
Thus, various stimuli activated Ca2+ signaling in osteoclasts, and the
signal appears to be comprised of Ca2+ released from intracellular stores,
and also entering the cell across the plasma membrane. One major
mechanism for activating Ca2+ entry across the plasma membrane is the
store-operated pathway [33]. To determine the role played by store-
operated channels in osteoclasts, Zaidi et al. [59] examined the effects of
thapsigargin, amembrane permeant inhibitor of the ER Ca2+ transporting
ATPase. When applied to osteoclasts, thapsigargin increased intracellular
Ca2+concentration inaCa2+ freebuffer, indicatingdischargeofCa2+ from
internal stores. The thapsigargin-induced Ca2+ elevation was augmented
upon restoration of extracellular Ca2+, indicating a stimulated Ca2+ inﬂux
in osteoclasts. Activation of Ca2+ inﬂux by thapsigargin is generally taken
as evidence for the store-operated Ca2+ entry pathway [3]. This type of
Ca2+ entry is blocked by several pharmacological agents such as
2-aminoethyldiphenyl borate, SKF-96365, and low concentration
(1–5 μM) of Gadolinium (Gd3+), and as discussed below, these agents
havebeen showntoaffect osteoclast signaling function [18,26]. Consistent
with Zaidi's observation, Shankar et al. [39] showed that store-depletion
by the Ca2+ ionophore, ionomycin, elicits a rapid and transient Ca2+
mobilization in Ca2+ free media, which becomes sustained after
restoration of extracellular Ca2+, indicating that two phases of Ca2+
signaling occur in osteoclasts, Ca2+ release followed by activation of Ca2+
inﬂux upon store depletion.
3. RANKL-evoked Ca2+ mobilization in osteoclasts
Two hematopoietic factors, receptor activator of nuclear factor-κB
ligand (RANKL) and macrophage-colony stimulating factor, are essen-
tial for osteoclastogenesis, [5,17,21,23,53,55]. Mature and functional
osteoclasts are formed from bone marrow-derived monocyte/macro-
phage precursor cells in the presence of these two required factors.
Importantly, Takayanagi [44] reported that cytosolic Ca2+ oscillations
occur not in response to IL-1 but rather to RANKL during osteoclasto-
genesis, suggesting the presence of signaling pathways speciﬁcally
activated by RANKL. These same authors reported that, on the basis of
genome wide screening, NFATc1 is speciﬁcally up-regulated by RANKL.
Interestingly, NFATc1 is known to be regulated by Ca2+/calmodulin-dependent calcineurin. They proposed that Ca2+ oscillations provide a
prolonged digital Ca2+ signal which activates calcineurin, leading to up-
regulation (and autoampliﬁcation) of NFATc1 and thereby promotes
osteoclastogenesis. In support of this idea, transient Ca2+mobilization by
Ca2+ ionophores such as ionomycin failed to up-regulate NFATc1 [44].
Furthermore, they showed that ectopic over-expression of NFATc1 is
sufﬁcient to induce osteoclastogenesis even in the absence of RANKL.
Subsequently, many other groups conﬁrmed the importance of RANKL-
induced Ca2+ oscillations in osteoclastogenesis. Yang and Li [51] showed
that genetic ablation of regulator of G-protein signaling 10 (RGS10)
abolishes RANKL-induced Ca2+ oscillations, leading to impaired up-
regulationofNFATc1andosteoclastogenesis. Theseauthorsdemonstrated
that over-expression of NFATc1 partially rescues the impaired osteoclas-
togenesis in RGS10−/− in the absence of RANKL. By using a proteomic
technique, Yoon et al. [54] found that Lyn, a Src family tyrosine kinase,was
down-regulated in RANKL-induced osteoclastogenesis which might
suggest a role of Lyn as a negative regulator during osteoclast
differentiation. Consistent with this idea, the same group observed that
knockdown of Lyn resulted in an increase in NFATc1 expression
accompanying Ca2+ oscillations. Knockdown of Lyn also promoted the
formation of both TRAP-positive multinucleated osteoclasts and resorp-
tion pits [54]. In addition, several studies have indicated that RANKL
induces a more immediate and transient Ca2+ elevation in isolated,
mature osteoclasts. Komarova et al. [20] observed that RANKL triggers an
intracellular Ca2+ rise in isolated rat osteoclasts. The Ca2+ rise was
apparently derived solely from an intracellular Ca2+ source, and signaled
translocationofNFκBand enhancedosteoclast survival. Chamouxet al. [7]
reported that RANKL elicited a rapid and sustained intracellular Ca2+ rise
in osteoclasts cultured from human blood. In this case, extracellular Ca2+
inﬂux appeared to be the major source of the Ca2+ signal.
4. Role of Ca2+ inﬂux in RANKL-evoked Ca2+ signaling
As described earlier, cytosolic Ca2+ oscillations occur during RANKL-
mediated osteoclastogenesis [44]. These oscillations are initiated by
activation of co-stimulatory receptors such as the osteoclast-associated
receptor and triggering receptor expressed on myeloid cells 2 after
binding of RANKL to RANK [19]. Subsequently, these receptors recruit the
spleen tyrosine kinase, which activates PLCγ by phosphorylation in a
concert with Tec-family kinases [41,42]. Activation of PLCγ triggers the
production of IP3, resulting in release of Ca2+ from theER. It is noteworthy
that in most cell types, activation of receptors coupled to PLC by high
concentrations of agonists triggers Ca2+ release from the ER followed by
Ca2+ inﬂux through store-operated Ca2+ entry (SOCE) [1,33]. Lower and
more physiological concentrations of receptor agonists induce repetitive
Ca2+ oscillations [2,46], similar to those seen in RANKL-mediated
osteoclast differentiation. SOCE is necessary to reﬁll the store in order to
maintain Ca2+ oscillations, which run down in the absence of SOCE [4].
Alternatively, SOCE in some instancesmay directly provide activator Ca2+
to trigger downstream responses [9]. In either case, store-operated Ca2+
(SOC) channel would be expected to play an important physiological role
in RANKL-induced Ca2+ signaling. Accordingly, Mentaverri et al. [26]
reported that inhibition of SOCE by two relatively non-speciﬁc SOC
channel blockers, 2-aminoethyldiphenyl borate and SKF-96365, dimin-
ished bone resorption activity of osteoclasts. Furthermore, a low
concentration of Gd3+, which is a relatively speciﬁc SOC channel blocker,
abolished RANKL-induced Ca2+ oscillations [18]. The same group also
demonstrated that knockdown of STIM1 which is a recently identiﬁed
SOC protein, signiﬁcantly reduces the frequency of RANKL-induced Ca2+
oscillations, suggesting that SOCE is an important component of the Ca2+
oscillations/calcineurin/NFATc1-dependent signaling complex induced
by RANKL.
However, the molecular identity of the channels responsible for the
Ca2+ inﬂux is far from a settled issue. Several recent studies have
focused on transient receptor potential (TRP) channels as candidates for
the channels underlying Ca2+ inﬂux in RANKL-induced Ca2+
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expressed in human and murine bone samples and in cultured
osteoclasts [47]. The TRPV5 was localized to the rufﬂed border
membrane of osteoclasts. Using a mouse model lacking the TRPV5
gene, VanderEerden et al. [47] concluded that TRPV5plays a critical role
in the function of osteoclasts since in vitro resorption activity was
attenuated in TRPV5−/− mice. However, the TRPV5−/− mice actually
displayed enhanced osteoclastogenesis [47]. Nonetheless, Hoenderop et
al. [14] observed that mice lacking TRPV5 exhibited a decrease in
trabecular and cortical thickness of long bones. Furthermore,Masuyama
et al. [25] reported an increase in bone mass in TRPV4−/− mice which
they attributed to impaired resorption activity of osteoclasts. ThemRNA
levels of NFATc1 were attenuated in cultured osteoclasts derived from
TRPV4−/− mice, while osteoblast phenotypes were not affected,
suggesting TRPV4 solely contributes to the differentiation and function
of osteoclasts. However, the same group found that TRPV4 was not
necessary to generate or to maintain Ca2+ oscillations in osteoclasts
since there was no signiﬁcant difference in the characteristic of Ca2+
oscillations betweenWT and TRPV4−/−mice (percentage of oscillating
cells, frequency and amplitude of Ca2+ oscillations). They concluded
that TRPV4 is more likely involved in Ca2+ inﬂux in large and mature
osteoclasts after Ca2+ oscillations have disappeared. They used 4α-PDD,
a speciﬁc TRPV4 agonist to show that TRPV4-mediated Ca2+ response
peaks at the later stage of osteoclasts, suggesting theremight be another
channel underlying Ca2+ inﬂux at the early stages of osteoclast
differentiation. Chamoux et al. [7] showed that knockdown of TRPV5
using TRPV5-targeted siRNA leads to inhibition of the RANKL-induced
Ca2+ inﬂux in human osteoclasts, which they suggest that TRPV5 is a
major player responsible for the RANKL-induced intracellular Ca2+ rise
in human osteoclasts. Despite the apparent role of TRPV5 in RANKL-
induced Ca2+ signaling in osteoclasts, knockdown of TRPV5 actually
promoted bone resorption. On this basis, Chamoux et al. [7] have
suggested that TRPV5 may function as a negative regulator of bone
homeostasis, similar to the inhibitory role of Lyn on the resorptive
activity of osteoclasts [54]. In addition to the Ca2+ channels described
above,Moonga et al. clearly demonstrated the expressionof aNa+/Ca2+
exchanger that contributes to the functional bone resorbing activity of
isolated rat osteoclasts [29].
5. Concluding remarks
Changes in intracellular Ca2+ concentrations are known to
function as universal triggers of diverse signaling pathways, includingTable 1
Summary of documented calcium signaling in osteoclasts.
Stimulus Type of Ca2+ res
Isolated chicken osteoclast Acidiﬁcation Decrease in [Ca2+
Isolated rabbit osteoclast ATP (50 μM) Rapid and transie




Isolated rabbit osteoclast Mechanical perturbation Rapid and transie
Bone-attached chicken osteoclast Acid secretion [Ca2+]i puffs
Human osteosarcoma lines, isolated rat
osteoblastic and osteoclastic cells
IP3 Transient increas
Isolated rat and chicken osteoclast High extracellular Ca2+ Rapid, various ty
Isolated rat osteoclast High extracellular Ca2+ Rapid and sustai
Osteoclast-like cells GCT23 High extracellular Ca2+ Rapid increase in
Isolated rat osteoclast Caffeine Rapid and transie
RANKL-differentiated osteoclast RANKL Delayed and spo
RANKL-differentiated osteoclast RANKL Delayed and spo
RANKL-differentiated osteoclast RANKL Delayed and spo
Isolated rat osteoclast RANKL Rapid and transie
Human osteoclast RANKL Rapid and sustai
ND: not determined
RANKL: receptor activator of nuclear factor-κB ligand.
[Ca2+]i: intracellular Ca2+ concentration.enzyme activation, cell survival and differentiation. Accordingly,
alterations in intracellular Ca2+ concentrations by different stimuli
also appear to regulate differentiation and functions of osteoclasts. A
summary of the variety of stimuli that can affect Ca2+ signaling in
osteoclasts is given in Table 1. There has been much progress in
understanding themolecular basis for differentiation and activation of
osteoclasts in the last decade following the discovery of RANKL
[21,23,53]. Yet, many questions still remain, especially regarding the
function of Ca2+ signaling. For example, bone mass was increased in
TRPV4−/− mice despite the fact that there was no effect on RANKL-
induced Ca2+ oscillations in osteoclasts [25]. Interestingly, Kuroda
et al. [22] reported that RANKL-induced Ca2+ oscillations are lost in
osteoclasts from IP3R type 2−/− mice, resulting in abolished
osteoclastogenesis. However, the osteoclastogenesis returned in the
absence of Ca2+ oscillations when the osteoclasts from IP3R type 2−/−
mice were co-cultured with osteoblasts. Furthermore, when osteo-
clastogenesis was induced in IP3R type 2−/− cells lacking Ca2+
oscillations, i.e., when mediated by co-culture with osteoblasts,
activation and translocation of NFATc1 were still induced, albeit
partially. This oscillation-independent induction of NFATc1 was
observed even in the presence of FK506, a calcineurin inhibitor.
Collectively, these ﬁndings suggest the existence of a possible
alternative pathway that is Ca2+ oscillations/calcineurin-independent
and activated by interaction of osteoblasts and osteoclasts.
An obvious take-home message from much of the above discussion
is the degree of uncertainty with regard to the Ca2+ signaling
mechanisms involved in osteoclastogenesis, especially with regard to
the route of Ca2+ entry across the plasma membrane. Although there
has been limitedwork in this area, there is ample evidence for the SOCE
pathway in osteoclasts [26]. In other cells of the hematopoietic lineage
SOCE is known to play an essential role in activating NFAT signaling
[12,32]. In just thepast fewyears, themolecular components underlying
SOCE have been revealed, in particular the components of the SOC
channels, Orai1, 2 and 3 [13,49,62]. Genetic deletion of Orai1 in mice
abolishes SOCE in some, but not all, hematopoietic cells [48]. Zhou et al.
[63] recently reported that knockdown of Orai1 abrogates the
osteoclastogenesis of human monocytes by suppressing multinuclea-
tion of precursor cells, suggesting the involvement of Orai1 channels in
osteoclastogenesis. However, many questions still remain yet. What is
the mechanism by which Orai1 regulates osteoclastogenesis? It is
possible that Ca2+ inﬂux through Orai1 channels activates NFAT, but
this has not been demonstrated. How does Orai1 inﬂuence the cell-cell
fusion of the osteoclasts? Is either Orai2 or 3 also involved? Is Orai1ponse Signiﬁcance of Ca2+ response References
]i Promote podosome formation [45]
nt increase in [Ca2+]i ND [56]
nt increase in [Ca2+]i ND [38]
nt increase in [Ca2+]i ND [50]
Osteoclastic acid secretion [34]
e in [Ca2+]i ND [11]
pes of increase in [Ca2+]i Osteoclast retraction [24]
ned increase in [Ca2+]i Resorption activity [58]
[Ca2+]i ND [37]
nt increase in [Ca2+]i ND [40]
ntaneous [Ca2+]i oscillations Osteoclast differentiation [44]
ntaneous [Ca2+]i oscillations Osteoclast differentiation [51]
ntaneous [Ca2+]i oscillations Osteoclast differentiation [54]
nt increase in [Ca2+]i Promotion of cell survival by nuclear
translocation of NFκB
[20]
ned increase in [Ca2+]i Resorption activity [7]
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store-operated Orai channels play in the process of bone resorption?
Further progress in understanding the signiﬁcance of SOCE and Orai
channels in Ca2+ oscillations/calcineurin/NFATc1-dependent osteoclas-
togenesis may provide a more complete molecular picture of the
mechanisms underlying Ca2+ signaling in bone. It will help our insight
in developing new therapeutic approaches for treatment of many bone
diseases in which excessive osteoclastic resorption is involved.
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